Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
T
T

ThermoFisher

Balita

Reuters - 1 linggo ang nakaraan

Bio-Techne meets Q4 profit estimates on demand for its diagnostics products

Bio-Techne meets Q4 profit estimates on demand for its diagnostics products Aug 7 (Reuters) - Bio-Techne TECH.O reported fourth-quarter profit in line with estimates on Wednesday as growth in the diagnostics and genomics unit offset weakness in its protein sciences unit. The Minnesota-based company posted an adjusted profit of 49 cents per share, meeting analysts' expectations according to LSEG data.
T
Reuters - 1 linggo ang nakaraan

Leerink views Lilly and Sarepta as defensive stocks in turbulent market

BUZZ-Leerink views Lilly and Sarepta as defensive stocks in turbulent market ** Brokerages Leerink Partners says Eli Lilly LLY.N and Sarepta Therapeutics SRPT.O are among stocks it expects to outperform the broader market in "this turbulent period" of recession concerns ** Brokerage expects strong performance from the weight-loss and diabetes drug maker LLY on Wed, when it reports its earnings ** SRPT is a "a potential haven for investors seeking downside protection in a choppy market" due to po
A
B
M
T
Reuters - 1 linggo ang nakaraan

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

UPDATE 1-Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims Adds response from Novartis in paragraph 3 By Blake Brittain Aug 5 (Reuters) - Novartis NOVN.S and Viatris VTRS.O were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
N
T
Reuters - 1 linggo ang nakaraan

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims By Blake Brittain Aug 5 (Reuters) - Novartis NOVN.S and Viatris VTRS.O were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development. The estate of Henrietta Lacks accused Novartis and Viatris of unlawfully profiting from the use of the "HeLa" cells to create drugs that have been "integral to their market pre
N
T
Reuters - 2 linggo ang nakaraan

China's stuttering recovery darkens global corporate growth outlook

ANALYSIS-China's stuttering recovery darkens global corporate growth outlook By Medha Singh Aug 2 (Reuters) - Global burger chains to car manufacturers are increasingly feeling the pinch from a faltering recovery in the world's No. 2 economy , China, and are strapping in for a bumpy ride ahead. A protracted downturn in the property market and high levels of job insecurity have knocked the wind out of a fragile recovery in China, a global trading powerhouse, and the effects of its slowdown can be
A
B
B
B
H
K
L
L
M
P
Q
S
T
T
Reuters - 2 linggo ang nakaraan

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products Aug 1 (Reuters) - Bio-Rad Laboratories BIO.N cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients. Shares of the diagnostics company fell 20% after the bell. Bio-Rad expects its full-year 2024 adjusted revenue to decline by about 2.5% to 4% on a currency-neutral basis, compared to its previous estimate of 1.0% to 2.5%.
T
W
Reuters - 2 linggo ang nakaraan

Waters Corp cuts annual profit forecast on weak demand for lab equipment

Waters Corp cuts annual profit forecast on weak demand for lab equipment July 31 (Reuters) - Waters Corp WAT.N lowered its annual profit forecast as it anticipates reduced demand for its products and services used in drug development and research. Milford, Massachusetts-based Waters supplies lab equipment and technology for scientists across the world, with the majority of its revenue coming in from biopharma clients who use its tools for research and drug development.
T
W
Reuters - 3 linggo ang nakaraan

Street View: Thermo's solid quarter signals easing demand weakness

BUZZ-Street View: Thermo's solid quarter signals easing demand weakness ** Thermo Fisher TMO.N raised its annual profit outlook on Wednesday and posted a better-than-expected profit in the second quarter, banking on improved demand for its tools and services used in clinical trials. SOLID QUARTER BY TMO SIGNALS RECOVERY ** RBC Capital Markets ("out
T
Reuters - 3 linggo ang nakaraan

U.S. STOCKS Tesla, Lamb Weston, Blackstone Mortgage Trust

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Lamb Weston, Blackstone Mortgage Trust Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq plummeted to a one-month low on Wednesday after Tesla and Alphabet disappointed with lackluster earnings, prompting investors to question if the Big Tech and AI-fueled 2024 equity rally was sustainable in the long run.
A
C
F
G
M
S
S
T
V
C
T
U
U
E
T
L
O
Reuters - 3 linggo ang nakaraan

U.S. STOCKS FTAI Aviation, Check Point, Sage Therapeutics

BUZZ-U.S. STOCKS ON THE MOVE-FTAI Aviation, Check Point, Sage Therapeutics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street fell on Wednesday, with the tech-heavy Nasdaq leading declines after lackluster quarterly results from Tesla and Alphabet raised questions about the sustainability of the Big Tech and AI-led 2024 equity rally.
A
F
G
M
S
T
V
C
T
U
U
E
T
L
O
Reuters - 3 linggo ang nakaraan

Thermo Fisher Scientific Inc reports results for the quarter ended in January - Earnings Summary

Thermo Fisher Scientific Inc reports results for the quarter ended in January - Earnings Summary Thermo Fisher Scientific Inc TMO.N reported quarterly adjusted earnings of $5.37​​ per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of $5.15. The mean expectation of twenty two analysts for the quarter was for earnings of $5.12 per share.
T
Reuters - 3 linggo ang nakaraan

Nasdaq futures set to slide at open after Tesla, Alphabet disappoint

US STOCKS-Nasdaq futures set to slide at open after Tesla, Alphabet disappoint For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Visa falls after missing revenue growth forecasts AT&T rises after beating subscriber-addition estimates Enphase Energy, Texas Instruments up after results Rivian falls; will face trial in Tesla trade secrets theft case Futures down: Dow 0.45%, S&P 500 0.90%, Nasdaq 1.39% Updated at 8:27 a.m.
A
A
G
M
N
T
V
T
U
U
U
T
Reuters - 3 linggo ang nakaraan

Thermo Fisher drops as raised profit forecast fails to impress Wall Street

REFILE-BUZZ-Thermo Fisher drops as raised profit forecast fails to impress Wall Street Corrects typo in company name in the headline ** Shares of medical equipment maker Thermo Fisher TMO.N down 3% at $535 premarket ** Co raises annual profit forecast to between $21.29 and $22.07 per share vs previous forecast of $21.14 to $22.02 ** Analysts were e
T
Reuters - 3 linggo ang nakaraan

Futures slide after Tesla, Alphabet earnings disappoint

US STOCKS-Futures slide after Tesla, Alphabet earnings disappoint For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. AT&T rises after beating subscriber-addition estimates Enphase Energy, Texas Instruments up after results Visa falls after missing revenue growth forecasts Rivian falls; will face trial in Tesla trade secrets theft case Futures down: Dow 0.42%, S&P 500 0.69%, Nasdaq 1.04% Updated at 6:54 a.m.
A
A
G
M
N
T
V
T
U
U
U
T
Reuters - 3 linggo ang nakaraan

Thermo Fisher lifts profit forecast as biotech demand shows signs of improvement

Thermo Fisher lifts profit forecast as biotech demand shows signs of improvement July 24 (Reuters) - Thermo Fisher TMO.N on Wednesday raised its annual profit outlook and posted a better-than-expected second-quarter profit, banking on improved demand for its tools and services used in clinical trials. Contract drug manufacturers witnessed cut back on spending by their biotech clients in 2023 amid rising interest rates.
T
Reuters - 3 linggo ang nakaraan

High earnings bar, Harris polling bump

MORNING BID AMERICAS-High earnings bar, Harris polling bump A look at the day ahead in U.S. and global markets from Mike Dolan Wall St has suddenly become a tough crowd to please. Much like last week's cool market reception for decent earnings beats from streamer Netflix NFLX.O or chipmaker TSMC 2330.TW , Alphabet's GOOGL.O surprisingly muscular second quarter left its stock down 2% overnight - and even the artificial intelligence theme didn't wow the gallery.
A
B
E
G
G
L
N
N
T
T
U
G
J
U
U
U
F
S
T
A
A
U
Reuters - 3 linggo ang nakaraan

Thermo Fisher Q2 Adjusted EPS USD 5.37 Vs. IBES Estimate USD 5.12

BRIEF-Thermo Fisher Q2 Adjusted EPS USD 5.37 Vs. IBES Estimate USD 5.12 Jul 24 (Reuters) - Thermo Fisher Q2 EPS USD 4.04. Q2 adjusted EBIT USD 2,347 million vs. IBES estimate USD 2,304 million Q2 adjusted net income USD 2,057 million vs. IBES estimate USD 1,963 million Q2 revenue USD 10,541 million vs. IBES estimate USD 10,511 million outlook FY re
T
Reuters - 3 linggo ang nakaraan

What to Watch in the Day Ahead - Wednesday, July 24

What to Watch in the Day Ahead - Wednesday, July 24 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Ford Motor is expected to post a drop in profit for the second quarter.
A
C
K
T
A
G
L
Reuters - 3 linggo ang nakaraan

Thermo Fisher Scientific Inc <TMO.N> expected to post earnings of $5.12 a share - Earnings Preview

Thermo Fisher Scientific Inc expected to post earnings of $5.12 a share - Earnings Preview Thermo Fisher Scientific Inc TMO.N , TMO is expected to show a fall in quarterly revenue when it reports results on July 24 for the period ending June 30 2024 The Waltham Massachusetts-based company is expected to report a 1.7% decrease in revenue to $10.511 billion from $10.69 billion a year ago, according to the mean estimate from 19 analysts, based on LSEG data.
T
Reuters - 4 linggo ang nakaraan

What to Watch in the Week Ahead and on Monday, July 22

What to Watch in the Week Ahead and on Monday, July 22 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY A meeting of the G20 finance ministers and central bank governors is scheduled to take place between July 22 and July 23, ahead of the G20 Brazil Summit 2024. The G20 finance ministe
A
B
C
G
M
T
V
C
H
T
G
L

Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.